Compare TGE & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TGE | MGNX |
|---|---|---|
| Founded | 2023 | 2000 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 94.9M |
| IPO Year | N/A | 2013 |
| Metric | TGE | MGNX |
|---|---|---|
| Price | $1.07 | $1.34 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.20 |
| AVG Volume (30 Days) | 374.5K | ★ 1.4M |
| Earning Date | 10-20-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $130,212,000.00 | $127,626,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.25 | ★ N/A |
| Revenue Growth | ★ 316.50 | N/A |
| 52 Week Low | $0.78 | $0.99 |
| 52 Week High | $37.02 | $3.64 |
| Indicator | TGE | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.08 |
| Support Level | N/A | $1.32 |
| Resistance Level | N/A | $1.47 |
| Average True Range (ATR) | 0.00 | 0.09 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 4.11 |
The Generation Essentials Group is a media and entertainment company. Its publications L'Officiel and The Art Newspaper publish print editions in a total of nearly 28 countries and territories and digital contents. It operate in the movie production sector having produced various Asia-focused movies. It operate in three operating segments: media and entertainment segment, hotel operations, hospitality and VIP services segment and strategic investment segment. Key revenue is generated from strategic investment segment that is engage in proprietary investments and management of portfolio, including listed and unlisted equity shares investments and movie income right investments.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.